Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2017-09, Vol.28, p.v441-v441 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | v441 |
|---|---|
| container_issue | |
| container_start_page | v441 |
| container_title | Annals of oncology |
| container_volume | 28 |
| creator | Arance, A. Dummer, R. Ascierto, P.A. Gogas, H. Mandala, M. Liszkay, G. Garbe, C. Schadendorf, D. Krajsová, I. Gutzmer, R. Chiarion Sileni, V. Dutriaux, C. de Groot, J.W.B. Yamazaki, N. Loquai, C. de Parseval, L.A. Pickard, M. Sandor, V. Robert, C. Flaherty, K.T. |
| description | |
| doi_str_mv | 10.1093/annonc/mdx377.030 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx377_030</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753420385069</els_id><sourcerecordid>S0923753420385069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1850-2e7f84417dc9d4f622d4dd76b592f56eb6e958aca89c193c74a652e2ffa3f893</originalsourceid><addsrcrecordid>eNp9kE1PGzEQhi1UpKbAD-htjs1hwV7vl9tTEoUSKSERhFxXE-9YuNq1kb1B0F_Tn9qEII6cRprRM--rh7Hvgl8KruQVOuedvuqaF1mWl1zyEzYQeaGSimfiCxtwlcqkzGX2lX2L8Q_nvFCpGrB_Nz4-2R5b-xd76x3cYU8RrIPJcv6wGD_cwwpDD-InjGD1iJFAwjpYbMEbmDrtAxpydgs_preT5RBW7S7C2DrbUW_f9uPZ7WwIGwpxf9lQt_sgNtPFEHyAA3mIHN-NrpPFrkfXw4JadL7Dc3ZqsI108T7P2Pp6up7cJPPl79lkNE-0qHKepFSaKstE2WjVZKZI0yZrmrLY5io1eUHbglReocZKaaGkLjMs8pRSY1CaSskzJo5vdfAxBjL1U7Adhtda8PpguD4aro-G673hPfPryNC-17OlUEdtyWlqbCDd1423n9D_AYvShDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma</title><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Arance, A. ; Dummer, R. ; Ascierto, P.A. ; Gogas, H. ; Mandala, M. ; Liszkay, G. ; Garbe, C. ; Schadendorf, D. ; Krajsová, I. ; Gutzmer, R. ; Chiarion Sileni, V. ; Dutriaux, C. ; de Groot, J.W.B. ; Yamazaki, N. ; Loquai, C. ; de Parseval, L.A. ; Pickard, M. ; Sandor, V. ; Robert, C. ; Flaherty, K.T.</creator><creatorcontrib>Arance, A. ; Dummer, R. ; Ascierto, P.A. ; Gogas, H. ; Mandala, M. ; Liszkay, G. ; Garbe, C. ; Schadendorf, D. ; Krajsová, I. ; Gutzmer, R. ; Chiarion Sileni, V. ; Dutriaux, C. ; de Groot, J.W.B. ; Yamazaki, N. ; Loquai, C. ; de Parseval, L.A. ; Pickard, M. ; Sandor, V. ; Robert, C. ; Flaherty, K.T.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx377.030</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2017-09, Vol.28, p.v441-v441</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1850-2e7f84417dc9d4f622d4dd76b592f56eb6e958aca89c193c74a652e2ffa3f893</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Arance, A.</creatorcontrib><creatorcontrib>Dummer, R.</creatorcontrib><creatorcontrib>Ascierto, P.A.</creatorcontrib><creatorcontrib>Gogas, H.</creatorcontrib><creatorcontrib>Mandala, M.</creatorcontrib><creatorcontrib>Liszkay, G.</creatorcontrib><creatorcontrib>Garbe, C.</creatorcontrib><creatorcontrib>Schadendorf, D.</creatorcontrib><creatorcontrib>Krajsová, I.</creatorcontrib><creatorcontrib>Gutzmer, R.</creatorcontrib><creatorcontrib>Chiarion Sileni, V.</creatorcontrib><creatorcontrib>Dutriaux, C.</creatorcontrib><creatorcontrib>de Groot, J.W.B.</creatorcontrib><creatorcontrib>Yamazaki, N.</creatorcontrib><creatorcontrib>Loquai, C.</creatorcontrib><creatorcontrib>de Parseval, L.A.</creatorcontrib><creatorcontrib>Pickard, M.</creatorcontrib><creatorcontrib>Sandor, V.</creatorcontrib><creatorcontrib>Robert, C.</creatorcontrib><creatorcontrib>Flaherty, K.T.</creatorcontrib><title>Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PGzEQhi1UpKbAD-htjs1hwV7vl9tTEoUSKSERhFxXE-9YuNq1kb1B0F_Tn9qEII6cRprRM--rh7Hvgl8KruQVOuedvuqaF1mWl1zyEzYQeaGSimfiCxtwlcqkzGX2lX2L8Q_nvFCpGrB_Nz4-2R5b-xd76x3cYU8RrIPJcv6wGD_cwwpDD-InjGD1iJFAwjpYbMEbmDrtAxpydgs_preT5RBW7S7C2DrbUW_f9uPZ7WwIGwpxf9lQt_sgNtPFEHyAA3mIHN-NrpPFrkfXw4JadL7Dc3ZqsI108T7P2Pp6up7cJPPl79lkNE-0qHKepFSaKstE2WjVZKZI0yZrmrLY5io1eUHbglReocZKaaGkLjMs8pRSY1CaSskzJo5vdfAxBjL1U7Adhtda8PpguD4aro-G673hPfPryNC-17OlUEdtyWlqbCDd1423n9D_AYvShDg</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Arance, A.</creator><creator>Dummer, R.</creator><creator>Ascierto, P.A.</creator><creator>Gogas, H.</creator><creator>Mandala, M.</creator><creator>Liszkay, G.</creator><creator>Garbe, C.</creator><creator>Schadendorf, D.</creator><creator>Krajsová, I.</creator><creator>Gutzmer, R.</creator><creator>Chiarion Sileni, V.</creator><creator>Dutriaux, C.</creator><creator>de Groot, J.W.B.</creator><creator>Yamazaki, N.</creator><creator>Loquai, C.</creator><creator>de Parseval, L.A.</creator><creator>Pickard, M.</creator><creator>Sandor, V.</creator><creator>Robert, C.</creator><creator>Flaherty, K.T.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201709</creationdate><title>Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma</title><author>Arance, A. ; Dummer, R. ; Ascierto, P.A. ; Gogas, H. ; Mandala, M. ; Liszkay, G. ; Garbe, C. ; Schadendorf, D. ; Krajsová, I. ; Gutzmer, R. ; Chiarion Sileni, V. ; Dutriaux, C. ; de Groot, J.W.B. ; Yamazaki, N. ; Loquai, C. ; de Parseval, L.A. ; Pickard, M. ; Sandor, V. ; Robert, C. ; Flaherty, K.T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1850-2e7f84417dc9d4f622d4dd76b592f56eb6e958aca89c193c74a652e2ffa3f893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arance, A.</creatorcontrib><creatorcontrib>Dummer, R.</creatorcontrib><creatorcontrib>Ascierto, P.A.</creatorcontrib><creatorcontrib>Gogas, H.</creatorcontrib><creatorcontrib>Mandala, M.</creatorcontrib><creatorcontrib>Liszkay, G.</creatorcontrib><creatorcontrib>Garbe, C.</creatorcontrib><creatorcontrib>Schadendorf, D.</creatorcontrib><creatorcontrib>Krajsová, I.</creatorcontrib><creatorcontrib>Gutzmer, R.</creatorcontrib><creatorcontrib>Chiarion Sileni, V.</creatorcontrib><creatorcontrib>Dutriaux, C.</creatorcontrib><creatorcontrib>de Groot, J.W.B.</creatorcontrib><creatorcontrib>Yamazaki, N.</creatorcontrib><creatorcontrib>Loquai, C.</creatorcontrib><creatorcontrib>de Parseval, L.A.</creatorcontrib><creatorcontrib>Pickard, M.</creatorcontrib><creatorcontrib>Sandor, V.</creatorcontrib><creatorcontrib>Robert, C.</creatorcontrib><creatorcontrib>Flaherty, K.T.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arance, A.</au><au>Dummer, R.</au><au>Ascierto, P.A.</au><au>Gogas, H.</au><au>Mandala, M.</au><au>Liszkay, G.</au><au>Garbe, C.</au><au>Schadendorf, D.</au><au>Krajsová, I.</au><au>Gutzmer, R.</au><au>Chiarion Sileni, V.</au><au>Dutriaux, C.</au><au>de Groot, J.W.B.</au><au>Yamazaki, N.</au><au>Loquai, C.</au><au>de Parseval, L.A.</au><au>Pickard, M.</au><au>Sandor, V.</au><au>Robert, C.</au><au>Flaherty, K.T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma</atitle><jtitle>Annals of oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>28</volume><spage>v441</spage><epage>v441</epage><pages>v441-v441</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdx377.030</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2017-09, Vol.28, p.v441-v441 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdx377_030 |
| source | Alma/SFX Local Collection; EZB Electronic Journals Library |
| title | Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T15%3A44%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hospitalization%20Rates%20in%20COLUMBUS%20Part%201:%20A%20Phase%203%20Trial%20of%20Encorafenib%20(ENCO)%20Plus%20Binimetinib%20(BINI)%20Versus%20Vemurafenib%20(VEM)%20or%20ENCO%20in%20BRAF-Mutant%20Melanoma&rft.jtitle=Annals%20of%20oncology&rft.au=Arance,%20A.&rft.date=2017-09&rft.volume=28&rft.spage=v441&rft.epage=v441&rft.pages=v441-v441&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx377.030&rft_dat=%3Celsevier_cross%3ES0923753420385069%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753420385069&rfr_iscdi=true |